Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

White, MT; Verity, R; Griffin, JT; Asante, KP; Owusu-Agyei, S; Greenwood, B; Drakeley, C; Gesase, S; Lusingu, J; Ansong, D; +28 more... Adjei, S; Agbenyega, T; Ogutu, B; Otieno, L; Otieno, W; Agnandji, ST; Lell, B; Kremsner, P; Hoffman, I; Martinson, F; Kamthunzu, P; Tinto, H; Valea, I; Sorgho, H; Oneko, M; Otieno, K; Hamel, MJ; Salim, N; Mtoro, A; Abdulla, S; Aide, P; Sacarlal, J; Aponte, JJ; Njuguna, P; Marsh, K; Bejon, P; Riley, EM; Ghani, AC; (2015) Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. The Lancet infectious diseases, 15 (12). pp. 1450-1458. ISSN 1473-3099 DOI: https://doi.org/10.1016/s1473-3099(15)00239-x

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/s1473-3099(15)00239-x

Abstract

Share

Download

Filename: mmc1.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar